Wells Fargo raised the firm’s price target on Crispr Therapeutics to $70 from $55 and keeps an Equal Weight rating on the shares. The firm thinks the focus for Crispr remains to be Casgevy launch dynamics in coming quarters, with additional focus on SLE CAR-T program entering clinic in the first half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Crispr Therapeutics options imply 7.2% move in share price post-earnings
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
- Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today
